-
03/27/2021
PAION RECEIVES EUROPEAN COMMISSION APPROVAL OF BYFAVO(R) (REMIMAZOLAM) FOR PROCEDURAL SEDATION
-
03/19/2021
PAION AG TO ISSUE APPROX. 5 MILLION SHARES AT EUR 1.54 PER SHARE IN CAPITAL INCREASE WITH SUBSCRIPTION RIGHTS
-
01/29/2021
PAION RECEIVES POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF BYFAVO(R) (REMIMAZOLAM) IN PROCEDURAL SEDATION
-
01/12/2021
PAION ANNOUNCES EXCLUSIVE LICENSING AGREEMENT WITH LA JOLLA PHARMACEUTICAL FOR GIAPREZA(TM) (ANGIOTENSIN II) AND XERAVA(TM) (ERAVACYCLINE) IN EUROPE
-
01/07/2021
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR REMIMAZOLAM (BYFAVO) IN GENERAL ANESTHESIA IN SOUTH KOREA